Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR.

Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.

PMID:
30266763
2.

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2.

Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR.

J Am Coll Surg. 2018 Apr;226(4):596-603. doi: 10.1016/j.jamcollsurg.2017.12.052. Epub 2018 Feb 7.

3.

Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C.

Sci Signal. 2014 May 6;7(324):ra42. doi: 10.1126/scisignal.2005049.

4.

Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.

Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR.

J Am Coll Surg. 2009 May;208(5):781-7; discussion 787-9. doi: 10.1016/j.jamcollsurg.2008.12.018.

5.

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.

Wang X, Ren H, Zhao T, Ma W, Dong J, Zhang S, Xin W, Yang S, Jia L, Hao J.

Oncotarget. 2016 Mar 22;7(12):13717-29. doi: 10.18632/oncotarget.7263.

6.

Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.

PMID:
25683115
7.

A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.

Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, Ji B, Huang H, Wang H, Fleming JB, Logsdon CD, Cruz-Monserrate Z.

Gastroenterology. 2013 Dec;145(6):1449-58. doi: 10.1053/j.gastro.2013.08.018. Epub 2013 Aug 16.

8.

Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL.

Clin Cancer Res. 2017 Jan 1;23(1):137-148. doi: 10.1158/1078-0432.CCR-16-0870. Epub 2016 Jun 28.

9.

Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z.

Cancer Res. 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1.

10.

Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.

Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim HG, Schoeb TR, Grizzle WE, Klug CA.

Cancer Res. 2007 Sep 1;67(17):8121-30.

11.

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses.

Køllgaard T, Klausen TW, Idorn M, Holmgaard RB, Straten PT, Andersen MH.

Oncoimmunology. 2012 Jul 1;1(4):441-447.

12.
13.

A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.

Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK.

Gastroenterology. 2013 Nov;145(5):1110-20. doi: 10.1053/j.gastro.2013.07.040. Epub 2013 Jul 27.

PMID:
23896173
14.

KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.

Yang K, Li Y, Lian G, Lin H, Shang C, Zeng L, Chen S, Li J, Huang C, Huang K, Chen Y.

Int J Cancer. 2018 Jun 1;142(11):2323-2334. doi: 10.1002/ijc.31248. Epub 2018 Jan 21.

15.

Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.

Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali C, Macinga P, Kaaks R, Stigliano S, Peeters PH, Key TJ, Talar-Wojnarowska R, Vodicka P, Valente R, Vashist YK, Salvia R, Papaconstantinou I, Shimizu Y, Valsuani C, Zambon CF, Gazouli M, Valantiene I, Niesen W, Mohelnikova-Duchonova B, Hara K, Soucek P, Malecka-Panas E, Bueno-de-Mesquita HBA, Johnson T, Brenner H, Tavano F, Fogar P, Ito H, Sperti C, Butterbach K, Latiano A, Andriulli A, Cavestro GM, Busch ORC, Dijk F, Greenhalf W, Matsuo K, Lombardo C, Strobel O, König AK, Cuk K, Strothmann H, Katzke V, Cantore M, Mambrini A, Oliverius M, Pezzilli R, Landi S, Canzian F.

Int J Cancer. 2018 Jan 15;142(2):290-296. doi: 10.1002/ijc.31047. Epub 2017 Oct 16.

16.

Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.

Zhang S, Chung WC, Xu K.

Oncogene. 2016 May 12;35(19):2485-95. doi: 10.1038/onc.2015.306. Epub 2015 Aug 17.

PMID:
26279302
17.

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.

Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B.

Mol Ther Nucleic Acids. 2019 Mar 1;14:301-317. doi: 10.1016/j.omtn.2018.11.019. Epub 2018 Dec 13.

18.

Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.

Wang WQ, Liu L, Xu HX, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ.

Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.

PMID:
27256393
19.

Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer.

Saloman JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, Rhim AD, Davis BM.

Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3078-83. doi: 10.1073/pnas.1512603113. Epub 2016 Feb 29.

20.

A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.

Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG.

J Gastrointest Oncol. 2018 Feb;9(1):1-10. doi: 10.21037/jgo.2017.10.14.

Supplemental Content

Support Center